Paul D. Smith

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

R W Wilkinson, B. Davies, S. Heaton, 2012, British Journal of Cancer.